Autres langues Spectral Medical Inc.

Actions

EDT

CA8475771033

Produits pharmaceutiques

Temps Différé Toronto S.E. Autres places de cotation 18:02:22 15/05/2026			Varia. 5j.	Varia. 1 janv.
1,400 ^CAD	-0,71 %		-2,10 %	-2,78 %

08/05	Spectral Medical Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI
26/03	Spectral Medical Inc. publie ses résultats annuels pour l'exercice clos le 31 décembre 2025	CI

Autres langues

08/05	Earnings Flash (EDT.TO) Spectral Medical Reports Q1 Revenue $0.9M, Vs $572k a Year Earlier
08/05	Spectral Medical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
08/05	Spectral Medical Announces First Quarter 2026 Financial Results and Provides Corporate Update
01/04	Spectral Medical Inc. Announces Participation in the 2026 Bloom Burton & Co. Healthcare Investor Conference
26/03	Spectral Medical Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
26/03	Earnings Flash (EDT.TO) Spectral Medical Reports Q4 Revenue C$0.4M, Loss From Continuing Ops of $2,838,000
26/03	Spectral Medical Swings to Q4 Loss
26/03	Earnings Flash (EDT.TO) Spectral Medical Reports Q4 Revenue C$0.4M, Profit From Continuing Ops of $2,838,000
26/03	Spectral Medical Announces Fourth Quarter and Fiscal 2025 Results and Provides Corporate Update
26/03	Spectral Medical Inc. Auditor Raises 'Going Concern' Doubt
24/03	Spectral Medical and Vantive Announce Publication of Complete Results from Spectral?S Tigris Trial in the Lancet Respiratory Medicine
24/03	Spectral Medical and Vantive Announce Publication of Complete Results from Spectral’s Tigris Trial in the Lancet Respiratory Medicine
26/02	Spectral Medical Provides Update on PMA Submission
26/02	Spectral Medical Inc. Provides Update on PMA Submission Timing for PMX-20R
26/02	Spectral Medical Provides Update on PMA Submission Timing for PMX-20R
07/11	Spectral Medical Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
07/11	Spectral Medical Provides Update on PMX Submission to FDA, Also Reports Q3 Loss
07/11	Spectral Medical Brief: Says PMA Submission Targeted for Q1 2026 Following "Positive" Tigris results and ongoing FDA interactions
07/11	Spectral Medical Brief: Total Q3 Revenue Increased to $675,000 compared to $502,000 for the same period in 2024
07/11	Spectral Medical Q3 revenue up 34%
07/11	Spectral Medical Announces Third Quarter 2025 Financial Results and Provides Corporate Update
29/09/25	Spectral Medical Inc. Files Base Shelf Prospectus and Revised AIF
16/09/25	Spectral Medical Provides Observational Study Update
16/09/25	Spectral Medical Inc. Announces Publication of Eden Observational Study
16/09/25	Spectral Medical Announces Publication of EDEN Observational Study